Zdenek Berger, PhD, is a neuroscience consultant for The Boston Consulting Group. In five years at Pfizer Neuroscience, Dr. Berger led the firm’s drug discovery program on glucocerebrosidase and biology efforts in the LRRK2 program. His previous research focused on protein degradation and autophagy, understanding biochemistry and activation of LRRK2 and putative toxic tau species.

Dr. Berger has studied neurodegeneration since 2002 with a focus on Parkinson’s disease since 2007. He serves as an ad-hoc reviewer for The Michael J. Fox Foundation and several journals. Dr. Berger has published numerous peer-reviewed publications and reviews with ~2,000 citations. He obtained his PhD at the University of Cambridge and subsequently completed postdoctoral training at Mayo Clinic and Harvard Medical School.